

Huntingtin - Pipeline Review, H1 2020

<https://marketpublishers.com/r/H0FA2536F3BFEN.html>

Date: March 2020

Pages: 87

Price: US\$ 3,500.00 (Single User License)

ID: H0FA2536F3BFEN

Abstracts

Huntingtin - Pipeline Review, H1 2020

SUMMARY

Huntingtin (Huntington Disease Protein or HTT) - Huntingtin protein is an encoded by the huntingtin gene, also called the HTT or HD (Huntington disease) gene. Huntingtin up regulates the expression of brain derived neurotrophic factor (BDNF) at the transcription level. Huntingtin is primarily associated with vesicles and microtubules. These indicate an important role in cytoskeletal anchoring or transport of mitochondria. The Htt protein is involved in vesicle trafficking as it interacts with HIP1 to mediate endocytosis. Huntingtin also plays an important role in the establishment in epithelial polarity through its interaction with RAB11A.

Huntingtin (Huntington Disease Protein or HTT) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Huntington Disease, Spinocerebellar Ataxia (SCA), Alzheimer's Disease, Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) and Spinal Muscular Atrophy (SMA).

The latest report Huntingtin - Pipeline Review, H1 2020, outlays comprehensive information on the Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted

therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Huntingtin (Huntington Disease Protein or HTT)

The report reviews Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics and enlists all their major and minor projects

The report assesses Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Huntingtin (Huntington

Disease Protein or HTT) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Huntingtin (Huntington Disease Protein or HTT)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Huntingtin (Huntington Disease Protein or HTT) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Huntingtin (Huntington Disease Protein or HTT) - Overview

Huntingtin (Huntington Disease Protein or HTT) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Huntingtin (Huntington Disease Protein or HTT) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Huntingtin (Huntington Disease Protein or HTT) - Companies Involved in Therapeutics Development

AFFiRiS AG

Dystrogen Therapeutics SA

Enzerna Biosciences LLC

Excicure Inc

F. Hoffmann-La Roche Ltd

Neurimmune Holding AG

Ophidion Inc

PTC Therapeutics Inc

reMYND NV

Takeda Pharmaceutical Co Ltd

UniQure NV

Voyager Therapeutics Inc

Vybion Inc

Wave Life Sciences Ltd

Huntingtin (Huntington Disease Protein or HTT) - Drug Profiles

AMT-130 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Inhibit HTT for Huntington's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Huntingtin (Huntington Disease Protein or HTT) - Dormant Products

Huntingtin (Huntington Disease Protein or HTT) - Product Development Milestones

Featured News & Press Releases

Feb 27, 2020: Ionis and partner highlight tominersen (formerly known as IONIS-HTTRx and RG6042) data at annual Huntington's disease drug discovery conference

Feb 27, 2020: uniQure presents multiple new preclinical data on AMT-130 at the CHDI's 15th Annual Huntington's Disease Therapeutics Conference

Feb 18, 2020: Wave Life Sciences to present preclinical in vivo and in vitro data for SNP3-targeting Huntington's Disease program at CHDI Foundation's 15th Annual HD Therapeutics Conference

Feb 17, 2020: Chugai receives orphan drug designation for RG6042 in Huntington's disease from the MHLW

Dec 30, 2019: Wave Life Sciences announces topline data and addition of higher dose cohort in ongoing Phase 1b/2a PRECISION-HD2 trial in Huntington's Disease

Dec 19, 2019: uniQure announces publication of preclinical data for AMT-130 in Huntington's disease supporting non-selective HTT-lowering approach

Sep 27, 2019: uniQure to present update on of AMT-130 at European Huntington Association 2019 Conference

Jul 01, 2019: Sangamo Therapeutics announces Nature Medicine publication detailing the activity of disease allele-selective zinc finger proteins in preclinical models of huntington's disease

May 22, 2019: uniQure strengthens intellectual property portfolio with granted patent claims covering AMT-130 for huntington's disease

May 07, 2019: uniQure announces featured presentations of new data on AMT-130 at the 2019 American Academy of Neurology Annual Meeting

May 06, 2019: Huntington drug successfully lowers levels of disease-causing protein

Apr 29, 2019: Genentech to present on its Huntington's Disease drug candidate RG-6042 at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio

Apr 15, 2019: uniQure to present data on Gene Therapy for Huntington's Disease at ASGCT 2019

Apr 10, 2019: Wave Life Sciences provides timing update on PRECISION-HD clinical programs

Apr 10, 2019: Wave Life Sciences provides timing update on WVE-120102 Clinical Program

Appendix

Methodology

Coverage

Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AFFiRiS AG, H1 2020
Pipeline by Dystrogen Therapeutics SA, H1 2020
Pipeline by Enzerna Biosciences LLC, H1 2020
Pipeline by Exicure Inc, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Neurimmune Holding AG, H1 2020
Pipeline by Ophidion Inc, H1 2020
Pipeline by PTC Therapeutics Inc, H1 2020
Pipeline by reMYND NV, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Pipeline by UniQure NV, H1 2020
Pipeline by Voyager Therapeutics Inc, H1 2020
Pipeline by Vybion Inc, H1 2020
Pipeline by Wave Life Sciences Ltd, H1 2020
Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AFFiRiS AG
Dystrogen Therapeutics SA
Enzerna Biosciences LLC
Exicure Inc
F. Hoffmann-La Roche Ltd
Neurimmune Holding AG
Ophidion Inc
PTC Therapeutics Inc
reMYND NV
Takeda Pharmaceutical Co Ltd
UniQure NV
Voyager Therapeutics Inc
Vybion Inc
Wave Life Sciences Ltd

I would like to order

Product name: Huntingtin - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/H0FA2536F3BFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H0FA2536F3BFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970